866-997-4948(US-Canada Toll Free)

Medullary Thyroid Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 58 Pages


Global Markets Directs, \'Medullary Thyroid Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Medullary Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer. 

Medullary Thyroid Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Medullary Thyroid Cancer.
  • A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Medullary Thyroid Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Medullary Thyroid Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Medullary Thyroid Cancer 7
Medullary Thyroid Cancer Therapeutics under Development by Companies 9
Medullary Thyroid Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Medullary Thyroid Cancer Therapeutics - Products under Development by Companies 14
Medullary Thyroid Cancer Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Medullary Thyroid Cancer Therapeutics Development 16
AstraZeneca PLC 16
Exelixis, Inc. 17
Globeimmune, Inc. 18
Medullary Thyroid Cancer - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
vandetanib - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
vandetanib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
cabozantinib - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
GI-6207 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
lithium carbonate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
sunitinib malate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
pasireotide - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Medullary Thyroid Cancer Therapeutics - Drug Profile Updates 35
Medullary Thyroid Cancer Therapeutics - Dormant Products 47
Medullary Thyroid Cancer - Product Development Milestones 48
Featured News & Press Releases 48
Sep 17, 2012: Exelixis Announces Data Presentations On Cabozantinib At ESMO 2012 Congress 48
Aug 29, 2012: Exelixis Provides Update On ODAC Panel For Thyroid Cancer Drug Cabozantinib 48
Jul 30, 2012: FDA Grants Priority Review For Cabozantinib In Medullary Thyroid Cancer 48
Jun 04, 2012: Exelixis Reports Pivotal Phase III Data Of Cabozantinib In Patients With Medullary Thyroid Cancer 49
May 30, 2012: Exelixis Completes Submission Of New Drug Application For Cabozantinib For Treatment Of Medullary Thyroid Cancer 51
Apr 02, 2012: Exelixis Features Cabozantinib In Nine Presentations At 2012 ASCO Annual Meeting 52
Feb 21, 2012: European Commission Approves AstraZeneca\'s CAPRELSA For Patients With Medullary Thyroid Cancer 53
Nov 18, 2011: AstraZeneca Announces CAPRELSA Receives Positive CHMP Opinion In EU For Treating Advanced Medullary Thyroid Cancer 54
Oct 24, 2011: Exelixis\'s Cabozantinib Meets Primary Endpoint In Phase III Clincial Trial For Medullary Thyroid Cancer 55
Sep 07, 2011: Exelixis Reaches Pre-Specified Number Of Events For Final Data Analysis In EXAM Trial 56

Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Table


Number of Products Under Development for Medullary Thyroid Cancer, H1 2013 7
Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
AstraZeneca PLC, H1 2013 16
Exelixis, Inc., H1 2013 17
Globeimmune, Inc., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Combination Products, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 24
Medullary Thyroid Cancer Therapeutics - Drug Profile Updates 35
Medullary Thyroid Cancer Therapeutics - Dormant Products 47

List of Chart


Number of Products under Development for Medullary Thyroid Cancer, H1 2013 7
Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 19
Assessment by Combination Products, H1 2013 20
Assessment by Route of Administration, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Molecule Type, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *